<DOC>
	<DOCNO>NCT01613118</DOCNO>
	<brief_summary>This study investigate whether RE-021 ( Sparsentan ) , selective dual-acting receptor antagonist affinity endothelin ( A type ) angiotensin II receptor ( Type 1 ) , safe effective treating patient focal segmental glomerulosclerosis ( FSGS ) .</brief_summary>
	<brief_title>Randomized , Double-Blind , Safety Efficacy Study RE-021 ( Sparsentan ) Focal Segmental Glomerulosclerosis</brief_title>
	<detailed_description>Focal segmental glomerulosclerosis ( FSGS ) rare glomerular disorder result frank proteinuria progression end-stage kidney disease ( ESKD ) 5-10 year . Proteinuria reduction widely regard beneficial , consider primary goal treatment FSGS slow progressive course ( D'Agati , et . al , 2011 ) . Patients currently treat steroid , calcineurin inhibitor , angiotensin receptor blocker ( ARB ) angiotensin convert inhibitor ( ACE ) low proteinuria ( Cameron , 2003 ) . Despite therapy , many patient nephrotic range proteinuria new therapeutic agent need ( Kiffel , et . al , 2011 ) . Endothelin receptor antagonist ( ERA ) show low proteinuria clinical trial diabetic nephropathy ( Kohan , et . al , 2011 ) ( Mann , et . al 2010 ) speculate effective FSGS ( Barton , 2010 ) .</detailed_description>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Inclusion Criteria 1 . Biopsyproven primary FSGS ( Primary FSGS confirm renal biopsy report ) OR documentation genetic mutation podocyte protein associate disease . 2 . Urine protein/creatinine ratio ( Up/C ) 1.0 g/g . 3 . Estimated glomerular filtration rate ( eGFR ) &gt; 30 . 4 . Mean seat blood pressure ( BP ) &gt; 100/60 mmHg &lt; 145/95 patient &gt; /= 18 year age . Mean seat BP patient &lt; 18 year age &gt; 90/60 mmHg &lt; 95th percentile age , gender , height . 5 . If patient take immunosuppressive medication ( except Rituximab cyclophosphamide ) , dose and/or level must stable 1 month prior randomization Investigator plan alter regimen first 8 week treatment , except stabilize level . Patients Rituximab cyclophosphamide eligible provide take medication 3 month prior randomization . 6 . US Sites : Males females 8 75 year age willing able provide write informed consent and/or assent , informed consent sign patient parent/legal guardian . 7 . EU Sites : Males females 18 75 year age willing able provide write informed consent , informed consent , sign patient legal guardian . Exclusion Criteria 1 . Patients FSGS secondary another condition . 2 . Patients history type 1 diabetes mellitus , uncontrolled type 2 diabetes mellitus ( HBA1c &gt; 8 % ) , nonfasting blood glucose &gt; 180 mg/dL screening . 3 . Patients organ transplant . 4 . Patients requirement medication indicate list Excluded Medications , exception ACE ARBs . 5 . Patients document history heart failure ( NYHA Class IIIV ) , / previous hospitalization heart failure unexplained dyspnea , orthopnea , paroxysmal nocturnal dyspnea , ascites peripheral edema . Patients clinically significant cerebrovascular disease ( transient ischemic attack stroke ) and/or coronary artery disease ( hospitalization myocardial infarction unstable angina , new onset angina positive functional test coronary angiogram reveal stenosis , coronary revascularization procedure ) within 6 month screen . 6 . Patients clinically significant cardiac conduction defect , include second third degree atrioventricular block , leave bundle branch block , sick sinus syndrome , atrial fibrillation , atrial flutter , accessory bypass tract , arrhythmia require medication . 7 . Patients jaundice , hepatitis , know hepatobiliary disease ( include asymptomatic cholelithiasis ) ; alanine aminotransferase and/or aspartate aminotransferase &gt; 2 time upper limit normal Screening . 8 . Patients positive human immunodeficiency virus ( HIV ) , marker indicate acute ( positivity least one following : Hepatitis B surface antigen [ HBsAg ] , Hepatitis B `` e '' antigen [ HBeAg ] , Hepatitis B virus [ HBV ] DNA blood liver , Immunoglobulin M Hepatitis B core antibody ) chronic ( HBsAg and/or HBeAg and/or Hepatitis B virus [ HBV ] DNA positivity ) HBV infection , hepatitis C virus ( HCV ) infection ( reactive antiHCV antibody and/or HCV RNA ) . Testing screening require patient &gt; /= 18 year age . 9 . History malignancy adequately treat basal cell squamous cell skin cancer within past 5 year . 10 . Patients hemodynamically significant valvular disease . 11 . Hematocrit ( HCT ) &lt; 27 hemoglobin ( Hgb ) &lt; 9 . 12 . Potassium &gt; 5.5 mEq/L . 13 . Patients &gt; 18 year age Estimated Glomerular Filtration Rate ( eGFR ) ≥60 ml mL/min Nterminal prohormone brain natriuretic peptide ( NTproBNP ) ≥200 pg/mL ( 57.8 pmol/L ) . For patient &gt; 18 year age eGFR &lt; 60 mL/min , follow parameter require echocardiography ( ECHO ) screen use exclusion : 1 . NTproBNP ≥300 pg/mL patient &gt; 18 year age eGFR 45 59.9 mL/min 2 . NTproBNP = 200299 pg/mL patient &gt; 18 year age eGFR 45 59.9 mL/min , abnormal ejection fraction ( EF &lt; 55 ) and/or diastolic dysfunction ECHO 3 . NTproBNP ≥400 pg/mL patient &gt; 18 year age eGFR 30.0 44.9 mL/min 4 . NTproBNP = 200399 pg/mL patient &gt; 18 year age eGFR 30.0 44.9 mL/min , abnormal ejection fraction ( EF &lt; 55 ) and/or diastolic dysfunction ECHO . 14 . Patients &gt; /= 18 year age body mass index ( BMI ) &gt; 40 . Patients &lt; 18 year age BMI 99 % percentile plus 5 unit . 15 . Patients abnormal clinical laboratory value Screening , designate Principal Investigator clinically significant . 16 . Patients history drug alcohol abuse within past two year . 17 . Patients history allergic response angiotensin II antagonist endothelin receptor antagonist . 18 . Women pregnant breastfeeding . 19 . Women childbearing potential ( WOCBP ) unwilling unable use two reliable method contraception , least one highly reliable ( e.g . oral , implanted inject contraceptive hormone intrauterine device ) one barrier method , order avoid pregnancy entire study period 90 day post study participation . WOCBP , define woman physiologically capable become pregnant , include female experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral ovariectomy ) postmenopausal ( define amenorrhea &gt; 12 consecutive month woman hormone replacement therapy , document plasma follicle stimulate hormone level great 35 mIU/mL ) . Women use oral , implanted inject contraceptive hormone , intrauterine device , barrier method ( diaphragm , condom , spermicidal ) prevent pregnancy , practice abstinence partner sterile ( e.g . vasectomy ) As well postmenopausal woman fertilize egg implant also consider WOCBP . 20 . Male patient female spouse/partners childbearing potential must use two reliable method contraception , least one highly reliable ( e.g . include oral , implanted inject contraceptive hormone intrauterine device ) one barrier method , e.g . condom , avoid pregnancy , entire study period 90 day post study participation . 21 . Patients participate another investigational drug study within 28 day prior screen , participate another drug study course study . 22 . Prior exposure Sparsentan , dual act receptor antagonist ( DARA ) , PS433540 . 23 . Patients unable comply study procedures assessment , include ability swallow study drug control capsule .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Primary FSGS</keyword>
	<keyword>Nephrotic syndrome</keyword>
	<keyword>Steroid Resistant</keyword>
</DOC>